Testing effectiveness (Phase 2)Ended earlyNCT03214666
What this trial is testing
GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies
Who this might be right for
High-risk Myelodysplastic SyndromesAcute Myelogenous LeukemiaSystemic Mastocytosis+1 more
GT Biopharma, Inc. 12